CA2666461A1 - Neuroprotective compositions and methods - Google Patents

Neuroprotective compositions and methods Download PDF

Info

Publication number
CA2666461A1
CA2666461A1 CA002666461A CA2666461A CA2666461A1 CA 2666461 A1 CA2666461 A1 CA 2666461A1 CA 002666461 A CA002666461 A CA 002666461A CA 2666461 A CA2666461 A CA 2666461A CA 2666461 A1 CA2666461 A1 CA 2666461A1
Authority
CA
Canada
Prior art keywords
composition
compound
acid
cell
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002666461A
Other languages
English (en)
French (fr)
Inventor
Stuart A. Lipton
Takumi Satoh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2666461A1 publication Critical patent/CA2666461A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/38—Unsaturated compounds containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002666461A 2006-10-10 2007-10-10 Neuroprotective compositions and methods Abandoned CA2666461A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85091806P 2006-10-10 2006-10-10
US85086006P 2006-10-10 2006-10-10
US60/850,860 2006-10-10
US60/850,918 2006-10-10
PCT/US2007/021748 WO2008108825A2 (en) 2006-10-10 2007-10-10 Neuroprotective compositions and methods

Publications (1)

Publication Number Publication Date
CA2666461A1 true CA2666461A1 (en) 2008-09-12

Family

ID=39738942

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002666461A Abandoned CA2666461A1 (en) 2006-10-10 2007-10-10 Neuroprotective compositions and methods

Country Status (5)

Country Link
US (2) US8022246B2 (enExample)
EP (1) EP2086318A4 (enExample)
JP (1) JP2010505958A (enExample)
CA (1) CA2666461A1 (enExample)
WO (1) WO2008108825A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105581999A (zh) 2007-02-06 2016-05-18 安元有限公司 用于抑制神经传导的包括萜烯化合物的组合物以及方法
CA2732784C (en) 2008-08-13 2018-09-18 Neuroquest Inc. Compositions comprising terpene compounds for treating negative sensory phenomena
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
GB2464813A (en) * 2009-10-23 2010-05-05 Univ Sheffield Treatments for neurodegenerative disorders
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
CA2811241A1 (en) * 2010-09-14 2012-03-22 Neuroquest Inc. Terpenoid analogues and uses thereof for treating neurological conditions
WO2012094580A2 (en) * 2011-01-07 2012-07-12 High Point Pharmaceuticals, Llc Compounds that modulate oxidative stress
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US20140256767A1 (en) 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
CN104220056B (zh) * 2012-03-30 2017-11-03 雀巢产品技术援助有限公司 4‑氧代‑2‑戊烯酸和脑健康
ES2617379T3 (es) 2012-04-13 2017-06-16 Epizyme, Inc. Forma de sal de un inhibidor de histona metiltransferasa EZH2 humana
BR112015008480A2 (pt) 2012-10-15 2017-07-04 Epizyme Inc compostos de benzeno substituído
US20150320795A1 (en) 2012-12-13 2015-11-12 Roy JOSEE Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury
ES2736599T3 (es) 2013-03-14 2020-01-03 Univ Macau Nuevos compuestos naturales antineurodegenerativos aislados a partir de Alpiniae oxyphyllae fructus y síntesis total de los mismos
PE20161273A1 (es) 2013-10-16 2016-12-18 Epizyme Inc Forma salina de hidrocloruro para la inhibicion de ezh2
CN107106537B (zh) * 2015-04-30 2020-07-17 杭州百诚医药科技股份有限公司 芳香族法尼基类化合物及其应用
US10123991B2 (en) 2015-05-15 2018-11-13 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
ES2767086T3 (es) 2015-06-15 2020-06-16 Neuralia Composición de combinación que comprende huperzina
EP3389646A1 (en) 2015-12-17 2018-10-24 BioElectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
CN111166885B (zh) * 2020-01-16 2022-03-15 上海交通大学医学院 神经保护剂及其用途
CN114588143B (zh) * 2020-12-03 2023-06-06 中国科学院大连化学物理研究所 药物组合物及化合物作为或在制备阿片受体拮抗剂中的应用
US20250122146A1 (en) * 2021-09-30 2025-04-17 The Scripps Research Institute Compounds for reducing neuroinflammation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3976782A (en) * 1975-03-25 1976-08-24 Merck & Co., Inc. 3-(2,5-Dihydroxyphenyl)-alanine as a cardiac stimulant
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1991013855A1 (en) * 1990-03-06 1991-09-19 Otsuka Pharmaceutical Co., Ltd. Phenanthrene derivative
DE69012566T2 (de) * 1990-10-06 1995-02-02 Nestle Sa Verfahren zur Gewinnung von Carnosäure.
CA2220223C (en) * 1995-05-05 2008-07-29 Hauser Inc. High purity carnosic acid from rosemary and sage extracts by ph-controlled precipitation
CA2286801C (en) * 1997-04-16 2006-03-14 Lycored Natural Products Industries Ltd. A novel process to produce stabilized carnosic acid in high concentration
JP2001233835A (ja) * 2000-02-28 2001-08-28 Nagase & Co Ltd カルノジン酸誘導体およびそれを用いた神経成長因子合成促進剤
AU2001271824A1 (en) * 2000-07-05 2002-01-14 Johns Hopkins School Of Medicine Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
AU2003231527A1 (en) * 2002-04-09 2003-10-27 Kemin Industries, Inc. Novel derivatives of carnosic acid
GB0216371D0 (en) * 2002-07-13 2002-08-21 Rowett Res Inst The Compounds
WO2004047772A2 (en) * 2002-11-26 2004-06-10 Florida Atlantic University Catalytic antioxidants and methods of use
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
ATE357932T1 (de) * 2003-12-22 2007-04-15 Alcon Inc Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie
MX2008004981A (es) * 2005-10-16 2008-10-17 Lycored Ltd Composiciones para el tratamiento de enfermedades de los ojos.

Also Published As

Publication number Publication date
US8466311B2 (en) 2013-06-18
WO2008108825A3 (en) 2008-12-18
EP2086318A4 (en) 2009-12-23
US8022246B2 (en) 2011-09-20
JP2010505958A (ja) 2010-02-25
US20090042980A1 (en) 2009-02-12
US20120296112A1 (en) 2012-11-22
WO2008108825A2 (en) 2008-09-12
EP2086318A2 (en) 2009-08-12

Similar Documents

Publication Publication Date Title
US8022246B2 (en) Neuroprotective compositions and methods
US20190000867A1 (en) Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
US20030199581A1 (en) Boswellin compositions enhanced with 3-beta-acetyl-11-keto-beta-boswellic acid ("AKBA") industrial manufacture and uses
CN102946877B (zh) 乳突果及其分离的化合物在制备用于治疗神经疾病的药物中的用途
Zhu et al. Neuroprotective effects of Astilbin on MPTP-induced Parkinson's disease mice: Glial reaction, α-synuclein expression and oxidative stress
US20210353591A1 (en) Enhancing autophagy or increasing longevity by administration of urolithins
Faysal et al. Neuropharmacological potential of honokiol and its derivatives from Chinese herb Magnolia species: understandings from therapeutic viewpoint
US20160143930A1 (en) Combination of pentacyclic triterpenes and hydroxytyrosol and derivatives thereof
Zhang et al. Comparison of inhibitory potency of three different curcuminoid pigments on nitric oxide and tumor necrosis factor production of rat primary microglia induced by lipopolysaccharide
CN103189056A (zh) L-dopa、多巴胺激动剂和/或多巴胺增强剂诱导的紊乱的治疗
Chen et al. Targeting the TLR4/NF-κB pathway in β-amyloid-stimulated microglial cells: A possible mechanism that oxysophoridine exerts anti-oxidative and anti-inflammatory effects in an in vitro model of Alzheimer’s disease
US9206103B2 (en) Materials and methods for reduction of protein tau and treatment of neurodegenerative diseases
Ahmadi et al. Therapeutic potential of cinnamon for neurological disorders: A mini-review.
Anggadiredja et al. The potential of Nigella sativa oil on clinical output improvement of diabetic neuropathy
EP3106160B1 (en) Combination composition comprising huperzine
JP3996505B2 (ja) ジベンゾシクロオクタン系リグナン化合物を含有する退行性脳神経系疾患の予防および治療効果を有する薬剤学的製剤
KR20250155546A (ko) 파킨슨병의 치료에 있어서의 메트포르민과 글리벤클라미드의 병용
CN110090216B (zh) 吲哚生物碱类化合物及其衍生物或盐在防治糖尿病肾病制品中的应用
dos Santos et al. Neuroprotection induced by apigenin
Ahmad et al. 19 Development of a Synergistic Combination of Huperzia
Han et al. Caffeolyquinic Acid Protects against Alzheimer’s Disease through Inhibition of Amyloid Beta-Induced Toxicity
KR20210073680A (ko) 내복자 추출물을 유효성분으로 함유하는 동맥경화 개선, 예방 또는 치료용 조성물
CN113041240A (zh) Act001在制备治疗帕金森药物和治疗nlrp3炎症小体介导的神经炎药物上的应用
Soumyanath et al. Research Article Centella asiatica Extract Improves Behavioral Deficits in a Mouse Model of Alzheimer’s Disease: Investigation of a Possible Mechanism of Action
WO2008089659A1 (fr) Utilisation de doubles inhibiteurs de transporteurs de dopamine et de transporteurs de noradrénaline

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20131010